Health
A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity – News-Medical.Net
As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome…
As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv* server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.
New approaches to spike-based vaccines
Both the viral spike antigen and its receptor-binding domain (RBD), which elicit highly potent neutralizing…
-
General24 hours agoTrump’s tariffs: a bad idea executed badly
-
Business4 hours agoSoaring one day, plunging the next. Why is the ASX 200 on a rollercoaster?
-
Business11 hours agoHow I’d build a $100,000 ASX portfolio from scratch
-
Noosa News6 hours agoBrisbane man Benjamin Holt speaks out about teen who allegedly organised Airbnb party that led to his house being trashed